A pioneering biotech firm has secured significant funding to develop ALS treatment.
- Trace Neuroscience, co-founded by experts from UCL and Stanford, is the firm behind this innovation.
- The focus lies on restoring UNC13A protein, crucial for neuronal communication in ALS patients.
- A substantial £79 million has been raised in a Series A funding round.
- Investors are showing strong interest in the therapeutic potential of UNC13A.
Trace Neuroscience, a newly established biotechnology company, has successfully raised £79 million in a Series A funding round. This infusion of capital is intended to advance the development of a novel treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease. The company, which benefits from an exclusive intellectual property licensing agreement with University College London (UCL), is co-founded by renowned molecular neuroscience professor Pietro Fratta and genetics professor Aaron Gitler of Stanford University.
The cornerstone of Trace Neuroscience’s research is the development of nucleic acids designed to restore the production of UNC13A, a protein essential for neuronal communication in both the brain and spinal cord. The decline of UNC13A is a prevalent issue in nearly all ALS cases, leading to the rapid progression of the disease and often resulting in patient mortality within five years. Professor Fratta believes that re-establishing UNC13A production could revolutionise treatments, describing the process as groundbreaking.
The Series A funding round, marked as one of the year’s largest in this sector, was spearheaded by Third Rock Ventures. Additional financial support was provided by Atlas Ventures, GV, and RA Capital Management. Caitriona O’Rourke, the business manager at UCL Business, expressed enthusiasm about the investment, highlighting the therapeutic potential and commercial viability of focusing on UNC13A as a treatment target.
The strategic partnership between Trace Neuroscience and UCL underscores the momentum behind innovative neurological research. By translating laboratory science into clinical applications, the company aims to bring effective treatment options to market, thus offering new hope to individuals afflicted by this debilitating condition.
The considerable investment and collaborative effort signal a promising step forward in ALS treatment development.
